AI Market Mood: Stock Dashboard
HRTX
Fundamental
Company: Heron Therapeutics Inc
Sector: Healthcare
Industry: Biotechnology
Country: USA
Exchange: NASD
Index: RUT
P/E: -
EPS (ttm): -0.08
Insider Own: 0.66%
Shs Outstand: 183.32M
Perf Week: 0.45%
Market Cap: 202.61M
Forward P/E: -
EPS next Y: 0.00
Insider Trans: 343.23%
Shs Float: 182.15M
Perf Month: -18.15%
Enterprise Value: 295.42M
PEG: -
EPS next Q: -0.02
Inst Own: 75.62%
Short Float: 19.15%
Perf Quarter: -16.92%
Income: -13.58M
P/S: 1.31
EPS this Y: -11.11%
Inst Trans: 3.25%
Short Ratio: 20.11
Perf Half Y: -40.91%
Sales: 155.10M
P/B: 28.84
EPS next Y Percentage: 100.00%
ROA: -5.78%
Short Interest: 34.87M
Perf YTD: -27.78%
Book/sh: 0.04
P/C: 3.65
EPS next 5Y: -
ROE: -
52W High: 2.68 -58.77%
Perf Year: -39.95%
Cash/sh: 0.30
P/FCF: -
EPS past 3/5Y: 65.87% 48.68%
ROIC: -8.79%
52W Low: 1.05 5.24%
Perf 3Y: -67.97%
Dividend Est.: -
EV/EBITDA: 66.24
Sales past 3/5Y: 18.67% -0.23%
Gross Margin: 73.92%
Volatility W: 5.58%
Volatility M: 6.55%
Perf 5Y: -93.27%
Dividend TTM: -
EV/Sales: 1.90
EPS Y/Y TTM: 58.23%
Oper. Margin: 1.35%
ATR (14): 0.07
Perf 10Y: -96.09%
Dividend Ex-Date: -
Quick Ratio: 1.78
Sales Y/Y TTM: 12.60%
Profit Margin: -8.75%
RSI (14): 38.11
Recom: 1.00
Dividend Gr. 3/5Y: - -
Current Ratio: 2.56
EPS Q/Q: -223.97%
SMA20: -5.86%
Beta: 1.35
Target Price: 4.50
Payout: -
Debt/Eq: 9.44
Sales Q/Q: 16.47%
SMA50: -10.74%
Rel Volume: 0.79
Prev Close: 1.11
Employees: 122
LT Debt/Eq: 9.39
Earnings: Nov 04 BMO
SMA200: -37.57%
Avg Volume: 1.73M
Price: 1.11
IPO: Aug 26, 1987
Option/Short: Yes / Yes
EPS/Sales Surpr.: -566.67% -2.10%
Trades:
Volume: 568,092
Change: -0.45%
Technical:
Latest News:
Heron Therapeutics (NASDAQ:HRTX) Earns Overweight Rating from Analysts at Capital ... somewhat bullish
HRTX
Summary: Capital One Financial initiated coverage on Heron Therapeutics with an overweight rating and a $6.00 price target. Other research analysts have also issued positive ratings for the company. Heron Therapeutics recently reported better-than-expected quarterly earnings. Institutional investors have shown interest in the company.
Full article2024-04-24T18:45:09Z
Capital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight Recommendation very bullish
HRTX
Summary: Capital One initiated coverage of Heron Therapeutics (NasdaqCM:HRTX) with an Overweight recommendation and a projected 175.68% upside in the stock price. Multiple institutional investors hold significant amounts of shares in Heron Therapeutics.
Full article2024-04-24T00:06:43Z